Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Benjamin Matthews

Nurse Practitioner, Family Olympia, WA Nurse Practitioner

NPI 1205372604 CMS profile 10836482

4250 Martin Way E Ste 105, Olympia, WA 98516

Open in the dashboard

General payments

$12,937

771 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Matthews of Olympia, WA is reported in the CMS Open Payments database as having received $12,937 across 771 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,956 169
2024 General $3,143 172
2023 General $3,683 206
2022 General $1,628 112
2021 General $1,528 112

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Matthews
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Benjamin Matthews were reported at $2,956. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Benjamin Matthews Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,528 $124 $35–$379 $132
2022 $1,628 $141 $44–$430 $149
2023 $3,683 $154 $49–$476 $160
2024 $3,143 $165 $51–$504 $164
2025 $2,956 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $3,652 244 payments
  2. AbbVie, Inc. $2,382 133 payments
  3. Amgen Inc. $1,002 52 payments
  4. Novartis Pharmaceuticals Corporation $943 80 payments
  5. Pfizer Inc. $874 74 payments
  6. UCB, Inc. $825 43 payments
  7. Sun Pharmaceutical Industries Inc. $579 25 payments
  8. Lilly USA, LLC $540 23 payments
  9. Organon LLC $376 24 payments
  10. E.R. Squibb & Sons, L.L.C. $332 16 payments
  11. Other $1,431 57 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,462 761 payments
  2. Education $475 10 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $3,317 214 payments
  2. SKYRIZI Immunology $1,083 62 payments
  3. Otezla $1,002 52 payments
  4. CIBINQO $822 71 payments
  5. RINVOQ $779 33 payments
  6. Bimzelx $570 27 payments
  7. TALTZ $497 21 payments
  8. COSENTYX $474 39 payments
  9. ILUMYA $442 23 payments
  10. SKYRIZI Immunology $425 33 payments
  11. Other $5,110 323 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

1,698

Median for Nurse Practitioner: 389

Drug cost

$2,834,616

Median for Nurse Practitioner: $21,885

Branded share of claims

21.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 65 $592,005
Tremfya Guselkumab Brand 40 $551,513
Skyrizi Pen Risankizumab-Rzaa Brand 18 $402,671
Cosentyx Sensoready (2 Pens) Secukinumab Brand 37 $392,346
Stelara Ustekinumab Brand 12 $270,031
Cosentyx Unoready Pen Secukinumab Brand 13 $176,810
Taltz Autoinjector Ixekizumab Brand 25 $173,551
Dupixent Pen Dupilumab Brand 22 $89,419
Adbry Tralokinumab-Ldrm Brand 15 $45,311
Dupixent Syringe Dupilumab Brand 11 $44,296

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$115,709

Of which drugs: $64

Medicare patients

601

Average age 72

Services billed

3,200

269 women, 332 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 56%
Arthritis 38%
Diabetes 26%
Ischemic heart disease 16%
Atrial fibrillation 16%
Depression 16%
Chronic kidney disease 14%
COPD 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$923 40 —
SKYRIZI
$374 18 —
RINVOQ
$242 — —
Bimzelx
$205 — —
ILUMYA
$195 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

771 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record